{"id":18340,"date":"2021-06-21T14:39:21","date_gmt":"2021-06-21T06:39:21","guid":{"rendered":"https:\/\/tbenews.com\/tbe\/?p=18340"},"modified":"2021-08-06T14:09:14","modified_gmt":"2021-08-06T06:09:14","slug":"snapshot-week-25-2021-a-vaccine-candidate-to-protect-against-powassan-virus-infection","status":"publish","type":"post","link":"https:\/\/tbenews.com\/tbe\/snapshot-week-25-2021-a-vaccine-candidate-to-protect-against-powassan-virus-infection\/","title":{"rendered":"Snapshot week 25\/2021
A vaccine candidate to protect against Powassan virus infection"},"content":{"rendered":"\n

Cimica et al.
A virus-like particle-based vaccine candidate against the tick-borne Powassan virus induces neutralizing antibodies in a mouse model.
Pathogens.<\/em> 2021; 10:680. doi: 10.3390\/pathogens10060680<\/p>\n\n\n\n

In North America and Far Eastern Russia, sporadic infections caused by Powassan virus (POWV) are reported. POWV belongs to the \u201ctick borne encephalitis virus serum complex\u201d and was first discovered and isolated in Ontario, Canada, in 1958. The fatality rate of neuroinvasive POWV cases is about 10%, and 50% of the cases result in permanent long-lasting sequelae. Currently, neither a vaccine nor specific therapeutics are available. Two lineages of POWV have been identified: lineage 1 is transmitted by Ixodes<\/em> cookei<\/em>, while lineage 2, also called deer tick virus, is transmitted by I<\/em>. scapularis<\/em>.<\/p>\n\n\n\n

A POWV vaccine candidate has been developed based on glycoprotein E (prM-E) and produced in a mammalian cell line (293T cells). Based on self-assembly, the recombinant protein forms virus-like particles (VLPs) and its structure resembles native virions with an icosahedral morphology typical for flaviviruses and sizes between 40 and 50 nm.<\/p>\n\n\n\n

POWV-VLPS were produced and purified in large scale and analyzed for its immunogenicity in BALB\/c mice. The antigen was injected three times by 3-week intervals, dosed with 1, 5 or 10 \u00b5g, and adjuvanted with a squalene-based oil-in-water nano emulsion (AddaVax).<\/p>\n\n\n\n

After the second injection with 10 \u00b5g of antigen, complete seroconversion was observed through analysis by ELISA and after the second booster dose, complete seroconversion was also observed with the lowest antigen dose. In a neutralization assay it was shown that POWV-VLPs elicited high level of neutralizing antibodies in a dose dependent manner.<\/p>\n\n\n\n

In addition, monoclonal antibodies against POWV were produced, which were reactive with POWV glycoprotein E antigen and POWV-VLPs, and which may represent potential candidates for therapeutic intervention against POWV infection.<\/p>\n<\/span>","protected":false},"excerpt":{"rendered":"

Cimica et al.A virus-like particle-based vaccine candidate against the tick-borne Powassan virus induces neutralizing antibodies in a mouse model.Pathogens. 2021; 10:680. doi: 10.3390\/pathogens10060680 In North America and Far Eastern Russia, sporadic infections caused by Powassan virus (POWV) are reported. POWV belongs to the \u201ctick borne encephalitis virus serum complex\u201d and was first discovered and isolated in Ontario, Canada, in 1958. The fatality rate of neuroinvasive POWV cases is about 10%, and 50% of the cases result in permanent long-lasting sequelae. Currently, neither a vaccine nor specific therapeutics are available. Two lineages of POWV have been identified: lineage 1 is transmitted by Ixodes cookei, while lineage 2, also called deer tick virus, is transmitted by I. scapularis. A POWV vaccine candidate has been developed based on glycoprotein E (prM-E) and produced in a mammalian cell line (293T cells). Based on self-assembly, the recombinant protein forms virus-like particles (VLPs) and its structure resembles native virions with an icosahedral morphology typical for flaviviruses and sizes between 40 and 50 nm. POWV-VLPS were produced and purified in large scale and analyzed for its immunogenicity in BALB\/c mice. The antigen was injected three times by 3-week intervals, dosed with 1, 5 or 10 \u00b5g, and adjuvanted with a squalene-based oil-in-water nano emulsion (AddaVax). After the second injection with 10 \u00b5g of antigen, complete seroconversion was observed through analysis by ELISA and after the second booster dose, complete seroconversion was also observed with the lowest antigen dose. In a neutralization assay it was shown that POWV-VLPs elicited high level of neutralizing antibodies in a dose dependent manner. In addition, monoclonal antibodies against POWV were produced, which were reactive with POWV glycoprotein E antigen and POWV-VLPs, and which may represent potential candidates for therapeutic intervention against POWV infection.<\/p>\n","protected":false},"author":1409,"featured_media":12864,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[18],"tags":[264,268,275,747,748,249,749],"coauthors":[81,652],"class_list":["post-18340","post","type-post","status-publish","format-standard","has-post-thumbnail","category-snapshot","tag-glycoprotein-e","tag-monoclonal-antibody","tag-neutralization-assay","tag-powassan-virus","tag-protection","tag-vaccine","tag-virus-like-antibodies"],"yoast_head":"\nSnapshot week 25\/2021 A vaccine candidate to protect against Powassan virus infection - TBE Book<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tbenews.com\/tbe\/snapshot-week-25-2021-a-vaccine-candidate-to-protect-against-powassan-virus-infection\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Snapshot week 25\/2021 A vaccine candidate to protect against Powassan virus infection - TBE Book\" \/>\n<meta property=\"og:description\" content=\"Cimica et al.A virus-like particle-based vaccine candidate against the tick-borne Powassan virus induces neutralizing antibodies in a mouse model.Pathogens. 2021; 10:680. doi: 10.3390\/pathogens10060680 In North America and Far Eastern Russia, sporadic infections caused by Powassan virus (POWV) are reported. POWV belongs to the \u201ctick borne encephalitis virus serum complex\u201d and was first discovered and isolated in Ontario, Canada, in 1958. The fatality rate of neuroinvasive POWV cases is about 10%, and 50% of the cases result in permanent long-lasting sequelae. Currently, neither a vaccine nor specific therapeutics are available. Two lineages of POWV have been identified: lineage 1 is transmitted by Ixodes cookei, while lineage 2, also called deer tick virus, is transmitted by I. scapularis. A POWV vaccine candidate has been developed based on glycoprotein E (prM-E) and produced in a mammalian cell line (293T cells). Based on self-assembly, the recombinant protein forms virus-like particles (VLPs) and its structure resembles native virions with an icosahedral morphology typical for flaviviruses and sizes between 40 and 50 nm. POWV-VLPS were produced and purified in large scale and analyzed for its immunogenicity in BALB\/c mice. The antigen was injected three times by 3-week intervals, dosed with 1, 5 or 10 \u00b5g, and adjuvanted with a squalene-based oil-in-water nano emulsion (AddaVax). After the second injection with 10 \u00b5g of antigen, complete seroconversion was observed through analysis by ELISA and after the second booster dose, complete seroconversion was also observed with the lowest antigen dose. In a neutralization assay it was shown that POWV-VLPs elicited high level of neutralizing antibodies in a dose dependent manner. In addition, monoclonal antibodies against POWV were produced, which were reactive with POWV glycoprotein E antigen and POWV-VLPs, and which may represent potential candidates for therapeutic intervention against POWV infection.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tbenews.com\/tbe\/snapshot-week-25-2021-a-vaccine-candidate-to-protect-against-powassan-virus-infection\/\" \/>\n<meta property=\"og:site_name\" content=\"TBE Book\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-21T06:39:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-08-06T06:09:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"250\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Michael Br\u00f6ker, IT\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Michael Br\u00f6ker, IT\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-25-2021-a-vaccine-candidate-to-protect-against-powassan-virus-infection\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-25-2021-a-vaccine-candidate-to-protect-against-powassan-virus-infection\\\/\"},\"author\":{\"name\":\"IT\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/person\\\/6dd4b733e0a9724f047e3b700d0995f6\"},\"headline\":\"Snapshot week 25\\\/2021 A vaccine candidate to protect against Powassan virus infection\",\"datePublished\":\"2021-06-21T06:39:21+00:00\",\"dateModified\":\"2021-08-06T06:09:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-25-2021-a-vaccine-candidate-to-protect-against-powassan-virus-infection\\\/\"},\"wordCount\":292,\"publisher\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-25-2021-a-vaccine-candidate-to-protect-against-powassan-virus-infection\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2017\\\/11\\\/TBE-Snapshots.jpg\",\"keywords\":[\"glycoprotein E\",\"monoclonal antibody\",\"neutralization assay\",\"Powassan virus\",\"protection\",\"vaccine\",\"virus-like antibodies\"],\"articleSection\":[\"Snapshot\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-25-2021-a-vaccine-candidate-to-protect-against-powassan-virus-infection\\\/\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-25-2021-a-vaccine-candidate-to-protect-against-powassan-virus-infection\\\/\",\"name\":\"Snapshot week 25\\\/2021 A vaccine candidate to protect against Powassan virus infection - TBE Book\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-25-2021-a-vaccine-candidate-to-protect-against-powassan-virus-infection\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-25-2021-a-vaccine-candidate-to-protect-against-powassan-virus-infection\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2017\\\/11\\\/TBE-Snapshots.jpg\",\"datePublished\":\"2021-06-21T06:39:21+00:00\",\"dateModified\":\"2021-08-06T06:09:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-25-2021-a-vaccine-candidate-to-protect-against-powassan-virus-infection\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-25-2021-a-vaccine-candidate-to-protect-against-powassan-virus-infection\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-25-2021-a-vaccine-candidate-to-protect-against-powassan-virus-infection\\\/#primaryimage\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2017\\\/11\\\/TBE-Snapshots.jpg\",\"contentUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2017\\\/11\\\/TBE-Snapshots.jpg\",\"width\":1180,\"height\":250},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-25-2021-a-vaccine-candidate-to-protect-against-powassan-virus-infection\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Snapshot week 25\\\/2021 A vaccine candidate to protect against Powassan virus infection\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#website\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/\",\"name\":\"The TBE Book\",\"description\":\"Tick-borne Encephalitis (TBE)\",\"publisher\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#organization\",\"name\":\"Global Health Press\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2019\\\/01\\\/logo-PNG.png\",\"contentUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2019\\\/01\\\/logo-PNG.png\",\"width\":1000,\"height\":715,\"caption\":\"Global Health Press\"},\"image\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/person\\\/6dd4b733e0a9724f047e3b700d0995f6\",\"name\":\"IT\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4df267d44fb154b70d642e56823f4ab2f6911852f88987e2bd5be087f7b3fa95?s=96&d=mm&r=g49b710224e606e5d7fddba562c9de771\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4df267d44fb154b70d642e56823f4ab2f6911852f88987e2bd5be087f7b3fa95?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4df267d44fb154b70d642e56823f4ab2f6911852f88987e2bd5be087f7b3fa95?s=96&d=mm&r=g\",\"caption\":\"IT\"},\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/author\\\/brianong\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Snapshot week 25\/2021 A vaccine candidate to protect against Powassan virus infection - TBE Book","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tbenews.com\/tbe\/snapshot-week-25-2021-a-vaccine-candidate-to-protect-against-powassan-virus-infection\/","og_locale":"en_US","og_type":"article","og_title":"Snapshot week 25\/2021 A vaccine candidate to protect against Powassan virus infection - TBE Book","og_description":"Cimica et al.A virus-like particle-based vaccine candidate against the tick-borne Powassan virus induces neutralizing antibodies in a mouse model.Pathogens. 2021; 10:680. doi: 10.3390\/pathogens10060680 In North America and Far Eastern Russia, sporadic infections caused by Powassan virus (POWV) are reported. POWV belongs to the \u201ctick borne encephalitis virus serum complex\u201d and was first discovered and isolated in Ontario, Canada, in 1958. The fatality rate of neuroinvasive POWV cases is about 10%, and 50% of the cases result in permanent long-lasting sequelae. Currently, neither a vaccine nor specific therapeutics are available. Two lineages of POWV have been identified: lineage 1 is transmitted by Ixodes cookei, while lineage 2, also called deer tick virus, is transmitted by I. scapularis. A POWV vaccine candidate has been developed based on glycoprotein E (prM-E) and produced in a mammalian cell line (293T cells). Based on self-assembly, the recombinant protein forms virus-like particles (VLPs) and its structure resembles native virions with an icosahedral morphology typical for flaviviruses and sizes between 40 and 50 nm. POWV-VLPS were produced and purified in large scale and analyzed for its immunogenicity in BALB\/c mice. The antigen was injected three times by 3-week intervals, dosed with 1, 5 or 10 \u00b5g, and adjuvanted with a squalene-based oil-in-water nano emulsion (AddaVax). After the second injection with 10 \u00b5g of antigen, complete seroconversion was observed through analysis by ELISA and after the second booster dose, complete seroconversion was also observed with the lowest antigen dose. In a neutralization assay it was shown that POWV-VLPs elicited high level of neutralizing antibodies in a dose dependent manner. In addition, monoclonal antibodies against POWV were produced, which were reactive with POWV glycoprotein E antigen and POWV-VLPs, and which may represent potential candidates for therapeutic intervention against POWV infection.","og_url":"https:\/\/tbenews.com\/tbe\/snapshot-week-25-2021-a-vaccine-candidate-to-protect-against-powassan-virus-infection\/","og_site_name":"TBE Book","article_published_time":"2021-06-21T06:39:21+00:00","article_modified_time":"2021-08-06T06:09:14+00:00","og_image":[{"width":1180,"height":250,"url":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg","type":"image\/jpeg"}],"author":"Michael Br\u00f6ker, IT","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Michael Br\u00f6ker, IT","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-25-2021-a-vaccine-candidate-to-protect-against-powassan-virus-infection\/#article","isPartOf":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-25-2021-a-vaccine-candidate-to-protect-against-powassan-virus-infection\/"},"author":{"name":"IT","@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/person\/6dd4b733e0a9724f047e3b700d0995f6"},"headline":"Snapshot week 25\/2021 A vaccine candidate to protect against Powassan virus infection","datePublished":"2021-06-21T06:39:21+00:00","dateModified":"2021-08-06T06:09:14+00:00","mainEntityOfPage":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-25-2021-a-vaccine-candidate-to-protect-against-powassan-virus-infection\/"},"wordCount":292,"publisher":{"@id":"https:\/\/tbenews.com\/tbe\/#organization"},"image":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-25-2021-a-vaccine-candidate-to-protect-against-powassan-virus-infection\/#primaryimage"},"thumbnailUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg","keywords":["glycoprotein E","monoclonal antibody","neutralization assay","Powassan virus","protection","vaccine","virus-like antibodies"],"articleSection":["Snapshot"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-25-2021-a-vaccine-candidate-to-protect-against-powassan-virus-infection\/","url":"https:\/\/tbenews.com\/tbe\/snapshot-week-25-2021-a-vaccine-candidate-to-protect-against-powassan-virus-infection\/","name":"Snapshot week 25\/2021 A vaccine candidate to protect against Powassan virus infection - TBE Book","isPartOf":{"@id":"https:\/\/tbenews.com\/tbe\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-25-2021-a-vaccine-candidate-to-protect-against-powassan-virus-infection\/#primaryimage"},"image":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-25-2021-a-vaccine-candidate-to-protect-against-powassan-virus-infection\/#primaryimage"},"thumbnailUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg","datePublished":"2021-06-21T06:39:21+00:00","dateModified":"2021-08-06T06:09:14+00:00","breadcrumb":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-25-2021-a-vaccine-candidate-to-protect-against-powassan-virus-infection\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tbenews.com\/tbe\/snapshot-week-25-2021-a-vaccine-candidate-to-protect-against-powassan-virus-infection\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-25-2021-a-vaccine-candidate-to-protect-against-powassan-virus-infection\/#primaryimage","url":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg","contentUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg","width":1180,"height":250},{"@type":"BreadcrumbList","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-25-2021-a-vaccine-candidate-to-protect-against-powassan-virus-infection\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tbenews.com\/tbe\/"},{"@type":"ListItem","position":2,"name":"Snapshot week 25\/2021 A vaccine candidate to protect against Powassan virus infection"}]},{"@type":"WebSite","@id":"https:\/\/tbenews.com\/tbe\/#website","url":"https:\/\/tbenews.com\/tbe\/","name":"The TBE Book","description":"Tick-borne Encephalitis (TBE)","publisher":{"@id":"https:\/\/tbenews.com\/tbe\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tbenews.com\/tbe\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/tbenews.com\/tbe\/#organization","name":"Global Health Press","url":"https:\/\/tbenews.com\/tbe\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/logo\/image\/","url":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2019\/01\/logo-PNG.png","contentUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2019\/01\/logo-PNG.png","width":1000,"height":715,"caption":"Global Health Press"},"image":{"@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/person\/6dd4b733e0a9724f047e3b700d0995f6","name":"IT","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/4df267d44fb154b70d642e56823f4ab2f6911852f88987e2bd5be087f7b3fa95?s=96&d=mm&r=g49b710224e606e5d7fddba562c9de771","url":"https:\/\/secure.gravatar.com\/avatar\/4df267d44fb154b70d642e56823f4ab2f6911852f88987e2bd5be087f7b3fa95?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4df267d44fb154b70d642e56823f4ab2f6911852f88987e2bd5be087f7b3fa95?s=96&d=mm&r=g","caption":"IT"},"url":"https:\/\/tbenews.com\/tbe\/author\/brianong\/"}]}},"_links":{"self":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts\/18340","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/users\/1409"}],"replies":[{"embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/comments?post=18340"}],"version-history":[{"count":1,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts\/18340\/revisions"}],"predecessor-version":[{"id":18341,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts\/18340\/revisions\/18341"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/media\/12864"}],"wp:attachment":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/media?parent=18340"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/categories?post=18340"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/tags?post=18340"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/coauthors?post=18340"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}